Polymer-drug systems

Patent metadata

Field	Value
Publication number	US-9545447-B2
Application number	US-201314043456-A
Country	US
Kind code	B2
Filing date	Oct 1, 2013
Priority date	Jan 4, 2013
Publication date	Jan 17, 2017
Grant date	Jan 17, 2017

Abstract

The present disclosure generally relates to polymer-drug systems, and more particularly to nanoscopic particles comprising amphiphilic block copolymers conjugated, physically encapsulated, or otherwise combined with chemotherapeutic agents along a selective region or regions of the backbone of the copolymer, so as to package the chemotherapeutic agent in selective domains within each nanoscopic particle, as well as to methods for making such particles, and applications and methods for using such particles, including in the formation of polymer micelles.

First claim

What is claimed is:

1. A composition comprising:
an amphiphilic block copolymer derived from poly(ethylbutyl phospholane)-block-poly (butynyl phospholane) (PEBP-b-PBYP) by modifying from poly(ethylbutyl phospholane)-block-poly (butynyl phospholane) (PEBP-b-PBYP) with a functionality comprising an anionic, cationic, zwitterionic, or neutral moiety or a combination thereof, the amphiphilic block copolymer comprising a hydrophobic-functional AB diblock polyphosphoester comprising at least one degradable polyphosphoester block; and
a chemotherapeutic agent.

2. The composition of claim 1 , wherein the amphiphilic block copolymer comprises a polymer backbone and the chemotherapeutic agent is conjugated with the copolymer along a selective region of the polymer backbone.

3. The composition of claim 1 , further comprising a pendant compound selected from the following group: a dye, an imaging agent, and a hydrophilic polymer, wherein the pendant compound is chemically reacted with the polyphosphoester via the reactive side chain functionality of the polyphosphoester.

4. The composition of claim 1 , wherein the block copolymer encapsulates the chemotherapeutic agent.

5. The composition of claim 1 , wherein the chemotherapeutic agent comprises paclitaxel (PTX).

6. A composition of comprising:
a poly(ethylbutyl phospholane)-block-poly (butynyl phospholane)-graft-polyethylene glycol (PEBP-b-PBYP-g-PEG) amphiphilic block copolymer; and
a chemotherapeutic agent.

7. The composition of claim 6 , wherein the amphiphilic block copolymer comprises a polymer backbone and the chemotherapeutic agent is conjugated with the copolymer along a selective region of the polymer backbone.

8. The composition of claim 6 , wherein the block copolymer encapsulates the chemotherapeutic agent.

9. The composition of claim 6 , wherein the chemotherapeutic agent comprises paclitaxel (PTX).

10. The composition of claim 6 , further comprising a pendant compound selected from the following group: a dye, an imaging agent, and a hydrophilic polymer, wherein the pendant compound is chemically reacted with the polyphosphoester via the reactive side chain functionality of the polyphosphoester.

Assignees

• Texas A & M Univ Sys

Inventors

• Wooley Karen
• Zou Jiong
• El Sabahy Mahmoud
• Zhang Shiyi
• Zhang Fuwu

Classifications

• A61K31/337

  having four-membered rings, e.g. taxol · CPC title

• A61K47/34 Primary

  Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence) · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K47/593

  Polyesters, e.g. PLGA or polylactide-co-glycolide · CPC title

• A61K47/59

  obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes · CPC title